Seer’s 2025 Scientific Impact:
Making Proteomics Population-Ready

2025 marked a turning point for proteomics—a year when the field moved decisively from potential to practice. Seer was at the forefront of that progress. Through landmark scientific publications, multiple population-scale studies, and Insight Grant–supported studies, Seer demonstrated how it is changing the arc of proteomics, delivering depth, accuracy, and scale without compromise. Together, these independent, high-impact efforts established Seer’s Proteograph platform as a foundation for population-scale, translationally credible proteomics.

And for the fifth consecutive year, Seer was also recognized as a Great Place to Work, reflecting the team and culture behind this progress.

Key scientific highlights from 2025 include:

• Trustworthy, scalable proteogenomics
  Karsten Suhre, PhD (Weill Cornell Medicine–Qatar), with collaborators from Harvard Medical School and Brigham and Women’s Hospital, published “A genome-wide association study of mass spectrometry proteomics using the Seer Proteograph platform.” Using Proteograph-enabled mass spectrometry, the team generated peptide-validated protein measurements broadening the catalog of genome-anchored biomarkers and showed that up to one-third of protein–gene associations from prior affinity-based studies failed to replicate with MS analysis.
• Independent technology benchmarking
  In “A Technical Evaluation of Plasma Proteomics Technologies,” Joshua J. Coon, PhD (University of Wisconsin–Madison) compared six plasma proteomics workflows. The nanoparticle-based Seer Proteograph XT delivered the deepest plasma proteome coverage, outperforming other mass-spec methods and an affinity-based platform, while maintaining strong reproducibility and quantifiability.
• Translational insight in complex biology
  In “Multi-omics analysis of a pig-to-human decedent kidney xenotransplant,” Brendan Keating, PhD (NYU Langone Health) used Seer-enabled deep proteomics to detect early molecular hallmarks of rejection, allow real-time treatment monitoring and establish a scalable framework for temporal sampling of transplant performance.
• Population-scale discovery in diverse cohorts
  Claudia Langenberg, MD, PhD, and Maik Pietzner, PhD (Queen Mary University of London) led “Nanoparticle enriched mass spectrometry proteomics in British South Asians identifies novel variant–protein–disease mechanisms.” Using Seer Proteograph XT at scale, the study uncovered and “unexplored reservoir of plasma proteins” that affinity-based approaches can miss including population-specific biology critical for global drug target validation.

Growing demand for Seer’s technology:

• In 2025, Seer was selected to power a 20,000-sample population proteomics study with Korea University focused on AI-driven cancer diagnostics in young adults, leveraging the Proteograph ONE™ Assay to accelerate analysis and reduce costs. Seer also awarded three Insights Grants to support Seer-enabled research at NYU, the University of Gothenburg, and Stanford.

Continued innovation with Proteograph^® ONE:

• The launch of Proteograph^® ONE, Seer’s most advanced product suite, reinforces this momentum. Designed for scalable, high-resolution mass-spectrometry-based proteomics, Proteograph ONE doubles throughput to over 1,000 samples per week per instrument, reduces per-sample costs by ~60% since Proteograph commercialization in 2021, and preserves Seer’s hallmark deep, unbiased proteome coverage—identifying up to 10× more proteins than traditional workflows.

Together, this work positions Seer as a driver of sustained progress in proteomics. By prioritizing rigor, scale, and biological validity, Seer-supported research strengthens confidence that future drug targets and biomarkers reflect real biology—laying the groundwork for more trustworthy proteomic maps that benefit researchers, clinicians, and patients.